DBV Technologies (DBVT) risk factors
Item 1A of every DBV Technologies S.A. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks6 new6 dropped14 reworded
DBV prepares for U.S. commercialization of the Viaskin Peanut patch following positive Phase 3 VITESSE results in children aged 4 to 7. Stallergenes Greer intends to discontinue Palforzia commercialization in July 2026. The company relies heavily on Sanofi and FAREVA for manufacturing.
Filed Mar 26, 2026 - FY2024 10-K risk factors75 risks
DBV Technologies is a clinical-stage biopharmaceutical company focused on its Viaskin technology platform, particularly Viaskin Peanut and Viaskin Milk. The company faces a severe risk of running out of cash, having incurred substantial net losses and an accumulated deficit of $286.4 million. Regulatory hurdles, reliance on third-party manufacturers, and clinical trial safety protocols such as oral food challenges dominate the risk profile.
Filed Apr 11, 2025